Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa, a wholly-owned subsidiary of Kyowa Hakko Kogyo, has entered into a second agreement with MedImmune to provide additional access to BioWa's Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.
Subscribe to our email newsletter
The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on Potelligent technology for an undisclosed number of targets. In return, BioWa receives from MedImmune certain fees and milestone payments during product development, as well as royalties on marketed products using antibody-dependent cellular cytotoxicity enhanced antibodies.
Dr Masamichi Koike, president and CEO of BioWa, said: “We are pleased to extend our relationship with MedImmune, a world-leading biologics business and the cornerstone to AstraZeneca’s plans to establish a major international presence in the R&D of biological therapeutics.”